发明授权
US09115371B2 Reduction of TGF beta signaling in myeloid cells in the treatment of cancer
有权
减少骨髓细胞TGFβ信号在治疗癌症中的作用
- 专利标题： Reduction of TGF beta signaling in myeloid cells in the treatment of cancer
- 专利标题（中）： 减少骨髓细胞TGFβ信号在治疗癌症中的作用
-
申请号： US13589769申请日： 2012-08-20
-
公开(公告)号： US09115371B2公开(公告)日： 2015-08-25
- 发明人: Li Yang
- 申请人： Li Yang
- 申请人地址： US DC Washington
- 专利权人： The United States of America, as represented by the Secretary, Department of Health and Human Services
- 当前专利权人： The United States of America, as represented by the Secretary, Department of Health and Human Services
- 当前专利权人地址： US DC Washington
- 代理机构： Leydig, Voit & Mayer, Ltd.
- 主分类号： A61K48/00
- IPC分类号： A61K48/00 ; C12N15/85 ; C12Q1/68 ; G01N33/50 ; G01N33/574 ; A61K31/5377 ; A61K31/7088 ; C12N15/113 ; C07K14/71 ; A61K35/15 ; A61K35/28
摘要：
Methods of inhibiting metastasis in cancer patients are provided, wherein the methods comprise reducing TGFβ signaling, for example, by reducing TGFβ receptor II expression in myeloid cells. Vectors comprising a TGFβ receptor II RNAi nucleic acid sequence operably linked to a myeloid specific promoter also are provided. A method of diagnosing cancer in an individual by determining TGFβ receptor II expression in myeloid cells in the individual is provided. Additionally, a method of modulating TGFβ activity in myeloid cells in a cancer patient comprising administering a regulator of at least one of the GSK3 and PI3K pathways to the patient is provided.
公开/授权文献
信息查询
